ABL Texcell Diagnostics Abandons Acquisition of Vela Diagnostics in Singapore and United States
The molecular diagnostics specialist based in Woippy announced in a press release issued on October 20, 2026 at 6:00 p.m. that the planned transaction in Singapore and the United States will not be completed. The project was intended to expand the group's commercial presence in Singapore and the American market.
Letter of Intent Signed in September Has Been Terminated
The letter of intent aimed at the acquisition of 100% of the capital of two entities: Vela Operations Singapore Pte. Ltd. and Vela Diagnostics USA Inc. It bound three parties: Vela Diagnostics Holding Pte. Ltd., ABL Texcell Diagnostics and Advanced Biological Laboratories S.A.
The project had been announced on September 21, 2026. It took the form of a non-binding letter of intent, presented as having no effect on the control or governance of the company.
According to the press release, this letter of intent has been terminated. As a result, the transaction it provided for will not take place.
The Group Continues Its Strategy Across Five Business Lines
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
ABL Texcell Diagnostics indicated that it is continuing the implementation of its development strategy. This covers molecular diagnostics, clinical genomics, health software, viral safety and specialized services intended for clinical research and biopharmaceutical development.
The company notably markets PCR detection tests (UltraGene) and genotyping solutions through DNA sequencing (DeepChek), via its own sales force and a network of exclusive distributors. Its patient record software Nadis is used in more than 200 hospitals in France for the monitoring of HIV and hepatitis.
A Second External Growth File Already Suspended in October
This termination comes just days after another development on the acquisitions front. On October 16, 2026, the company reported a notice of appeal filed by the public prosecutor at the Judicial Court of Évry-Courcouronnes, challenging the decision that had designated it as part of the takeover of IntegraGen.
Furthermore, on October 2, 2026, the group had raised its 2026 revenue target to a range of €13.5 million to €14.0 million. This increase incorporated the contribution of Texcell activities, acquired in the second half.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
1 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 12,3 millions d'euros
Management commentary: On June 1, 2026, ABL Diagnostics published a roadmap targeting annual revenue of €12.265 million in 2026, compared to €6.950 million in 2025, i.e. a targeted annual growth of 76.5%.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
